Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How Will Valneva's COVID Vaccine Setback Impact Dynavax?

TheMotleyFool

0 0

How Will Valneva's COVID Vaccine Setback Impact Dynavax?Photo, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Several companies are using CpG 1018, an adjuvant developed by Dynavax Technologies (NASDAQ: DVAX), in developing their COVID-19 vaccines. One of them, French biotech Valneva (NASDAQ:VALN), has recently received some bad news with the U.K. canceling a supply deal. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss how Valneva's setback might impact Dynavax.

Source Fool.com

Like: 0

DVAX

Share